Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Finland

Finland

The projected revenue in the Other Vaccines market in Finland is expected to reach US$96.33m in 2024.
This is anticipated to show an annual growth rate (CAGR 2024-2029) of 10.02%, leading to a market volume of US$155.30m by 2029.
In comparison to other countries, United States is forecasted to generate the highest revenue, with US$24,730.00m in 2024.
Finland has witnessed an increasing demand for other vaccines, driven by a strong public healthcare system and high awareness about the importance of immunization.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Finland has been experiencing steady growth in recent years.

Customer preferences: Finland has a highly vaccinated population, with a strong emphasis on preventative healthcare. As a result, there is a high demand for vaccines in the country. The Finnish government has also been proactive in promoting vaccination programs, particularly for children and the elderly.

Trends in the market: One of the key trends in the Other Vaccines market in Finland is the increasing popularity of travel vaccines. As more Finns travel abroad, there is a growing need for vaccinations against diseases such as yellow fever and hepatitis A. In addition, there has been a rise in demand for vaccines related to lifestyle factors, such as the HPV vaccine for sexually transmitted infections.

Local special circumstances: Finland has a highly developed healthcare system, which includes a strong focus on preventative care. As a result, there is a high level of trust in vaccines among the Finnish population. In addition, the country has a relatively small population, which makes it easier to implement vaccination programs and track their effectiveness.

Underlying macroeconomic factors: Finland is a developed country with a high standard of living and a strong economy. This has allowed the government to invest in healthcare infrastructure and preventative care programs, including vaccination programs. In addition, Finland has a well-educated population with a high level of health literacy, which has contributed to the success of vaccination campaigns.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.